Voyager Therapeutics announces retirement of chief scientific officer Dinah Sah
Voyager Therapeutics announced the retirement of Dinah Sah, Ph.D. as Voyager's chief scientific officer, and the appointment by Voyager of Omar Khwaja, M.D., Ph.D., currently Voyager's chief medical officer, to the expanded role of chief medical officer and head of research and development. Both changes will be effective June 28, 2019. Dr. Sah has agreed to serve as a consultant to Voyager and become a member of its scientific advisory board. "We are grateful to Dinah for all of her contributions to Voyager since its inception. We are pleased that she intends to stay actively involved in our future and that we will continue to benefit from her scientific insight as a consultant and key scientific advisor," said Andre Turenne, president and chief executive officer of Voyager. "Omar is well positioned to assume leadership for our research efforts. His broad management experience and translational medicine expertise will be critical strengths as he assumes this additional role and continues to drive forward our gene therapy programs and platform."